Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

被引：0

作者：

Richardson, Paul ^{[1
]}

Sandhu, Irwindeep ^{[2
]}

Oriol, Albert ^{[3
,4
]}

Raab, Marc S. ^{[5
]}

White, Darrell ^{[6
,7
]}

LeBlanc, Richard ^{[8
]}

Perrot, Aurore ^{[9
]}

Ocio, Enrique ^{[10
]}

Raje, Noopur ^{[11
]}

Hansen, Charlotte Toftmann ^{[12
]}

Zhou, Zehua ^{[13
]}

Civardi, Tiziana ^{[14
]}

Ghiddi, Alessandro ^{[14
]}

Katz, Jessica ^{[13
]}

Peluso, Teresa ^{[14
]}

Dimopoulos, Meletios A. ^{[15
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Alberta, Edmonton, AB, Canada

[3] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[4] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain

[5] Univ Klinikum Heidelberg, Heidelberg, Germany

[6] Dalhousie Univ, Halifax, NS, Canada

[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[8] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada

[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[10] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain

[11] Massachusetts Gen Canc Ctr, Boston, MA USA

[12] Odense Univ Hosp, Odense, Denmark

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Celgene Int Sarl, Boudry, Switzerland

[15] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-053

引用

页码：S33 / S33

页数：1

共 50 条

[41] A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Chari, A.
Htut, M.
Zonder, J.
Fay, J.
Jakubowiak, A.
Harrison, B.
Lau, K.
Burt, S.
Hilder, B.
Ptaszynski, A. M.
Rush, S.
Kaufman, J.
HAEMATOLOGICA, 2014, 99 : 113 - 113
[42] A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
Richardson, Paul G.
Amatangelo, Michael
Berenson, James R.
Cerchione, Claudio
Dimopoulos, Meletios A.
Hansen, Charlotte Toftmann
Hwang, Soo Jeong
Koo, Phillip
Kuroda, Junya
Oriol, Albert
Orlowski, Robert Z.
Quach, Hang
Raab, Marc S.
Rocci, Alberto
Wang, Yue
White, Darrell
Yu, Brian
Zhou, Zehua
Katz, Jessica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
Jakubowiak, Andrzej J.
White, Darrell
Moreau, Philippe
Facon, Thierry
Vij, Ravi
Kroog, Glenn Scott
Kopit, Justin
Singhal, Anil
Palumbo, Antonio Pierangelo
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[44] Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)
Badros, A. Z.
Philip, S.
Niesvizk, R.
Goloubeva, O.
Harris, C.
Zweibel, J.
Wright, J. J.
Burger, A.
Baer, M. R.
Egorin, M. J.
Grant, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[45] A Phase 1 study Of CC-92480, a novel CELMoD agent, in patients with relapsed/refractory multiple myeloma: pharmacodynamic effects of dose and schedule
Wong, Lilly
Lamba, Manisha
Jimenez Nunez, Maria Dolores
Bauer, Daniel
Bahlis, Nizar J.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Pourdehnad, Michael
Pierce, Daniel W.
Richardson, Paul G.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 152 - 153
[46] First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
van de Donk, Niels W. C. J.
Popat, Rakesh
Zonder, Jeffrey A.
Minnema, Monique C.
Larsen, Jeremy
Tuong Vi Nguyen
Chen, Min S.
Bensmaine, Amine
Cota, Mariana
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[47] Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
Hansen, Joshua D.
Correa, Matthew
Nagy, Mark A.
Alexander, Matt
Plantevin, Veronique
Grant, Virginia
Whitefield, Brandon
Huang, Dehua
Kercher, Timothy
Harris, Roy
Narla, Rama Krishna
Leisten, Jim
Tang, Yang
Moghaddam, Mehran
Ebinger, Katalin
Piccotti, Joseph
Havens, Courtney G.
Cathers, Brian
Carmichael, James
Daniel, Thomas
Vessey, Rupert
Hamann, Lawrence G.
Leftheris, Katerina
Mendy, Derek
Baculi, Frans
LeBrun, Laurie A.
Khambatta, Gody
Lopez-Girona, Antonia
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) : 6648 - 6676
[48] OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses
Richardson, Paul G.
Schjesvold, Fredrik H.
Abdulhaq, Haifaa
Coriu, Daniel
Lazzaro, Antonio
Sonneveld, Pieter
Kullenburg, Torbjorn
Harmenberg, Johan
Thuresson, Marcus
Byrne, Catriona
Mateos, Maria-Victoria
BLOOD, 2021, 138
[49] Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).
Jakubowiak, Andrzej
Wang, Luhua
Orlowski, Robert Z.
Jagannath, Sundar
Siegel, David
Stewart, A. Keith
Kukreti, Vishal
Lonial, Sagar
McDonagh, Kevin T.
Vallone, Marcy
Kauffman, Michael
Vij, Ravi
BLOOD, 2009, 114 (22) : 725 - 726
[50] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
Chen, Christine I.
Bahlis, Nizar J.
Gasparetto, Cristina
Tuchman, Sascha A.
Lipe, Brea
Baljevic, Muhamed
Kotb, Rami
Sutherland, Heather J.
Bensinger, William I.
Sebag, Michael
LeBlanc, Richard
Venner, Christopher P.
Schiller, Gary J.
Lentzsch, Suzanne
Callander, Natalie S.
Rossi, Adriana C.
Sheehan, Heidi
Van Domelen, Dane
Kazuharu, Kai
Wang, Hongwei
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
White, Darrell J.
BLOOD, 2020, 136

← 1 2 3 4 5 →